Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03567057 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
A Phase 3 study, sponsored by Adamas Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 424
- Enrollment target
NCT03567057: Completed Phase 3 study, sponsored by Adamas Pharmaceuticals.
NCT03567057 is a Phase 3 study that has completed, run by Adamas Pharmaceuticals. The registered enrollment target is 424 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03567057, a Phase 3 study, has completed, sponsored by Adamas Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 424 participants
- Enrollment target
Study Summary
This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).
Primary Outcome
The incidence of treatment-emergent adverse events was used as the measure for long-term safety and tolerability of ADS-5102.
Interventions
- DRUG ADS-5102, 274 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2018-07-18 |
| Est. Completion | 2021-04-18 |
| Phase | Phase 3 |
What the finished NCT03567057 record still lists
NCT03567057 is an interventional study that assigns participants to a tested intervention. The registered 424 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 1 intervention - of which ADS-5102, 274 mg is the first listed.
NCT03567057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03567057 about?
NCT03567057 is a clinical study titled "A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment". This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).
What is the current status of trial NCT03567057?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 424 participants. The study started on 2018-07-18. Estimated completion is 2021-04-18.
What interventions are being tested in trial NCT03567057?
The interventions under investigation include: ADS-5102, 274 mg (DRUG).
Who is sponsoring clinical trial NCT03567057?
This trial is sponsored by Adamas Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03567057's enrollment target sits among peer trials
424 884th of 2000 higher than 1,116 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
- NCT06978127 · 424 participants · NA
Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients
- NCT07140913 · 424 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI